by European Hematology Association
In these EHA-produced podcasts, experts share with you their hematology knowledge and stories. With "EHA Unplugged" we would like to give you the opportunity to unplug from your computer screen, while still learning, by listening to interviews, clinical cases, monologues, and more.
Language
🇺🇲
Publishing Since
9/1/2021
Email Addresses
0 available
Phone Numbers
0 available
April 18, 2025
<p>Join us for a conversation between prof. Kirsten Gronbaek and her guest prof. Dominik Wolf, as they discuss targeting the immune system in MDS management. In light of accumulating evidence that inflammatory signals play a role throughout disease evolution in MDS patients, prof. Wolf elucidates the current insights and possible future therapeutic options. </p><p>He uses the example of targeting NLRP3/IL-1 axis in low-risk MDS to highlight the need of understanding the underlying cellular biology to translate that knowledge into clinical approaches. He also discusses the concept of possibly targeting both non-clonal and clonal compartments for better patient outcomes in the future. </p><p>Tune in, to hear about other future directions in treatment of MDS, such as recent developments in CAR T-cell approaches and about the central role that allo-transplantation is likely to keep in the treatment of high-risk MDS. You will also hear about the potential link between inflammation and fatigue, which is clinically highly relevant, but as yet an unsolved issue in MDS. </p><p>Host: prof. Kirsten Gronbaek</p><p>Guest: prof. Dominik Wolf</p><h2>Learn More</h2><p><br></p><p>What did you think of this podcast? Share your opinions with us in this short feedback survey.</p><p><a href="https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1" rel="noopener noreferrer" target="_blank">https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1</a></p><p><br></p><p>Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.</p><p><a href="https://ehacampus.ehaweb.org/" rel="noopener noreferrer" target="_blank">https://ehaedu.org/Campus</a></p><p><br></p><p>Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.</p><p>Follow EHA on Instagram: <a href="https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged" rel="noopener noreferrer" target="_blank">https://www.instagram.com/EHA_Hematology/</a></p><p>Facebook: <a href="https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged" rel="noopener noreferrer" target="_blank">https://e-h-a.link/facebook</a></p><p>LinkedIn: <a href="https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged" rel="noopener noreferrer" target="_blank">https://www.linkedin.com/company/eha/</a></p><p>Email us: [email protected]</p><p>Subscribe to receive the EHA Educational Updates via <a href="https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged" rel="noopener noreferrer" target="_blank">https://eha.news/subscribe</a> </p>
April 11, 2025
<p>Listen to Dr. Jan Moritz Middeke from University Hospital in Dresden as he discusses the future of clinical trials in hematology and the role artificial intelligence (AI) may play in that field. Dr. Middeke explains how synthetic data is generated and what are the potential benefits and limitations of its use in clinical trials. He also points out the open questions and hurdles that need to be addressed before AI-generated synthetic patients can be included in clinical trial design. </p><p>Tune in to hear how Dr. Middeke envisages the role of AI in solving the challenges of clinical trials for rare malignant diseases and how it may accelerate data generation and access to novel therapies. </p><p>If you want to know more: </p><p><a href="https://www.nature.com/articles/s41746-024-01076-x" rel="noopener noreferrer" target="_blank">https://www.nature.com/articles/s41746-024-01076-x</a> </p><p>Host: Isabel Olivera-Martinez, PhD, Medical Writer </p><p>Guest: Dr. Jan Moritz Middeke</p><h2>Learn More</h2><p><br></p><p>What did you think of this podcast? Share your opinions with us in this short feedback survey.</p><p><a href="https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1" rel="noopener noreferrer" target="_blank">https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1</a></p><p><br></p><p>Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.</p><p><a href="https://ehacampus.ehaweb.org/" rel="noopener noreferrer" target="_blank">https://ehaedu.org/Campus</a></p><p><br></p><p>Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.</p><p>Follow EHA on Instagram: <a href="https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged" rel="noopener noreferrer" target="_blank">https://www.instagram.com/EHA_Hematology/</a></p><p>Facebook: <a href="https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged" rel="noopener noreferrer" target="_blank">https://e-h-a.link/facebook</a></p><p>LinkedIn: <a href="https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged" rel="noopener noreferrer" target="_blank">https://www.linkedin.com/company/eha/</a></p><p>Email us: [email protected]</p><p>Subscribe to receive the EHA Educational Updates via <a href="https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged" rel="noopener noreferrer" target="_blank">https://eha.news/subscribe</a> </p>
April 4, 2025
<p>In this episode, Dr. Onima Chowdhury, a hematologist from the University Hospital in Oxford, talks about the diagnostic workup of Myelodysplastic Syndromes (MDS). With a focus on both clinical practice and research, Dr. Chowdhury outlines the essential steps and tests required for diagnosing MDS, discusses the role of morphology, cytogenetics, and the significance of NGS panels in the diagnostic process. </p><p>The conversation also touches on the potential of artificial intelligence in diagnostics, the prognostic value of genetic mutations, and the importance of considering germline disorders in MDS. This episode is a must-listen for healthcare professionals seeking to deepen their understanding of MDS diagnostics. </p><p>Host: Prof Kirsten Grønbæk</p><p>Guest: Dr Onima Chowdhury</p><h2>Learn More</h2><p><br></p><p>What did you think of this podcast? Share your opinions with us in this short feedback survey.</p><p><a href="https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1" rel="noopener noreferrer" target="_blank">https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1</a></p><p><br></p><p>Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.</p><p><a href="https://ehacampus.ehaweb.org/" rel="noopener noreferrer" target="_blank">https://ehaedu.org/Campus</a></p><p><br></p><p>Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.</p><p>Follow EHA on Instagram: <a href="https://www.instagram.com/EHA_Hematology/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged" rel="noopener noreferrer" target="_blank">https://www.instagram.com/EHA_Hematology/</a></p><p>Facebook: <a href="https://e-h-a.link/facebook?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged" rel="noopener noreferrer" target="_blank">https://e-h-a.link/facebook</a></p><p>LinkedIn: <a href="https://www.linkedin.com/company/eha/?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged" rel="noopener noreferrer" target="_blank">https://www.linkedin.com/company/eha/</a></p><p>Email us: [email protected]</p><p>Subscribe to receive the EHA Educational Updates via <a href="https://eha.news/subscribe?utm_medium=podcast&utm_source=bcast&utm_campaign=eha-unplugged" rel="noopener noreferrer" target="_blank">https://eha.news/subscribe</a> </p>
British Society for Haematology
American Society of Hematology
Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
NEJM Group
The Hematologist
Goalhanger
Goalhanger
Wondery
DOAC
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.